|
|
|
| Clinical effect of pulmonary surfactant combined with Budesonide in the treatment of premature infants with severe respiratory distress syndrome |
| CHEN Jing1 JIANG Xiaohua2 SHEN Weiqi1 |
1.Department of Neonatology, People’s Hospital of Hechuan District of Chongqing, Chongqing 401520, China;
2.Department of Neonatology, Fuling Central Hospital Affiliated to Chongqing Medical University, Chongqing 408000, China |
|
|
|
Abstract Objective To investigate the clinical effect of pulmonary surfactant (PS) combined with Budesonide in the treatment of premature infants with severe respiratory distress syndrome (RDS). Methods A total of 168 premature infants with severe RDS admitted in People’s Hospital of Hechuan District of Chongqing from July 2016 to December 2019 were selected. They were divided into control group and study group according to the random number table method, With 84 cases in each group. The control group was treated with PS, and the study group was treated with Budesonide on the basis of the control group. The clinical efficacy, inflammatory factors (Interleukin-6 [IL-6], tumor necrosis factor-α [TNF-α]), blood gas analysis (oxygenation index [OI], arterial partial pressure of carbon dioxide [PaCO2], arterial partial pressure of oxygen [PaO2]) and complications of two groups were compared. Results After 72 hours of treatment, PaO2 and OI in two groups were higher than those before treatment, and study group was higher than control group (all P < 0.05). PaCO2 in two groups were lower than those before treatment, and study group was lower than control group (all P < 0.05). The total effective rate of study group was higher than that of control group (P < 0.05). The levels of serum IL-6 and TNF-α in two groups were lower than those before treatment, and study group was lower than control group (all P < 0.05). There was no significant difference in the total incidence rate of complications between two groups (P > 0.05). Conclusion PS combined with Budesonide in the treatment of severe RDS premature infants can effectively reduce the level of inflammatery factors, improve the level of blood gas analysis, which is safe and effective.
|
|
|
|
|
|
[1] Morrell ED，Mikacenic C，Gong KQ，et al. Alveolar MMP28 is associated with clinical outcomes and measures of lung injury in acute respiratory distress syndrome [J]. Crit Care，2020，24（1）：141.
[2] Carla A，Pereira B，Boukail H，et al. Acute respiratory distress syndrome subphenotypes and therapy responsive traits among preclinical models：protocol for a systematic review and meta-analysis [J]. Respir Res，2020，21（1）：81.
[3] Zhao J，Tan Y，Wang L，et al. Serum sphingosine-1-phosphate levels and Sphingosine-1-Phosphate gene polymorphisms in acute respiratory distress syndrome：a multicenter prospective study [J]. J Transl Med，2020，18（1）：156.
[4] 刘慧强，童笑梅，韩彤妍，等.微创应用肺表面活性物质治疗早产儿呼吸窘迫综合征失败的高危因素分析[J].中国当代儿科杂志，2020，22（3）：231-237.
[5] 尹晓娟，张宣，陈佳，等.布地奈德干预治疗重度新生儿急性呼吸窘迫综合征的临床分析[J].发育医学电子杂志，2020，8（1）：47-52.
[6] 邵肖梅，叶鸿瑁，丘小汕.实用新生儿学[M].北京：人民卫生出版社，2011.
[7] Orsini J，Gawlak H，Sabayev V，et al. Pneumocystis jirovecii Pneumonia-Associated Acute Respiratory Distress Syndrome Complicated by Pneumomediastinum and Pneumopericardium in a Non-Human Immunodeficiency Virus-Infected Patient [J]. J Clin Med Res，2020，12（3）：209-213.
[8] Cheng ZB，Chen H. Higher incidence of acute respiratory distress syndrome in cardiac surgical patients with elevated serum procalcitonin concentration：a prospective cohort study [J]. Eur J Med Res，2020，25（1）：11.
[9] Lilly CM，Khan S，Waksmundzki-Silva K，et al. Vaping-Associated Respiratory Distress Syndrome：Case Classification and Clinical Guidance [J]. Crit Care Explor，2020，2（2）：e0081.
[10] 向蕊，曲书强.糖皮质激素联合肺表面活性物质治疗新生儿呼吸窘迫综合征研究进展[J].中国医师进修杂志，2019，42（12）：1141-1145.
[11] Madotto F，Rezoagli E，Pham T，et al. Hyperoxemia and excess oxygen use in early acute respiratory distress syndrome：insights from the LUNG SAFE study [J]. Crit Care，2020，24（1）：125.
[12] 黎首豪，黄书炜，蔡玉青.新生儿急性呼吸窘迫综合征治疗中肺表面活性物质的疗效[J].中国医药科学，2020， 10（1）：166-168.
[13] 王超.高频震荡通气联合肺泡表面活性物质治疗新生儿呼吸窘迫综合征的应用价值[J].中国现代医生，2019， 57（26）：58-61.
[14] 林玲，彭好.肺泡表面活性物质在新生儿呼吸窘迫综合征中的微创应用[J].中华实用儿科临床杂志，2019，34（23）：1834-1837.
[15] 林勇，孙晓玄，许楠.布地奈德联合猪肺磷脂注射液对重度新生儿呼吸窘迫综合征患儿肺功能的影响[J].药物评价研究，2019，42（9）：1835-1838.
[16] 王耀霜，杨曼，韩萍，等.布地奈德混悬液氧驱雾化吸入法防治早产儿支气管肺发育不良的效果[J].临床和实验医学杂志，2019，18（19）：2121-2124.
[17] 钟俊炎，宗海峰，叶楠，等.持续性肺膨胀联合肺表面活性物质治疗新生儿呼吸窘迫综合征的效果：前瞻性随机对照试验[J].中华围产医学杂志，2019，22（11）：781-786.
[18] 李群，倪文昌，邬慧明，等.肺表面活性物质联合布地奈德预防新生儿呼吸窘迫综合征的疗效观察[J].海军医学杂志，2019，40（1）：54-57.
[19] 周栩平，周静，胡冰，等.布地奈德联合肺表面活性物质对重症呼吸窘迫综合征早产儿近期疗效、血氧指标及支气管肺发育不良发生风险的影响[J].儿科药学杂志，2019，25（11）：27-30.
[20] 王君，王建民，崔福英，等.不同布地奈德给药方式联合PS对呼吸窘迫综合症患儿肺功能及安全性的影响[J].国际呼吸杂志，2019，39（15）：1163-1168.
[21] 刘萍，张雪飞.乌司他汀联合俯卧位通气在重症肺炎合并急性呼吸窘迫综合征早期临床应用分析[J].中国药物与临床，2018，18（11）：2030-2031.
[22] 郝新华，贺红岩，王梦莹.高频振荡通气序贯不同无创通气模式治疗早产儿呼吸窘迫综合征的效果分析[J].中国临床医生杂志，2020，48（7）：865-868.
[23] 蔡琳，李晓东，张升荣，等.布地奈德联合肺表面活性物质治疗新生儿呼吸窘迫综合征的临床研究[J].中外医学研究，2020，18（29）：8-11.
[24] 王生寿，王菊萍.布地奈德联合肺表面活性物质雾化吸入对重度新生儿呼吸窘迫综合征的研究[J].检验医学与临床，2018，15（10）：1524-1527.
[25] 平莉莉，张淑彦，翟淑芬.二联支气管药物滴注方案对重症呼吸窘迫综合征早产儿临床预后的影响[J].中国医师进修杂志，2019，42（2）：154-157.
[26] 赵金章，刘玲.布地奈德联合肺表面活性物质治疗新生儿呼吸窘迫综合征疗效观察[J].儿科药学杂志，2018， 24（9）：17-19.
[27] 苏超云，叶旭芳.肺表面活性物质、布地奈德联合鼻塞式持续气道正压通气治疗新生儿呼吸窘迫综合征的临床效果[J].中国当代医药，2019，26（31）：159-161，165.
[28] 邓黎静，彭华保，龚晓琴.布地奈德联合肺表面活性物质治疗重症呼吸窘迫综合征对支气管肺发育不良的影响[J].中华新生儿科杂志：中英文，2017，32（5）：361-364. |
|
|
|
